PSA screening declines following publication of large trials, guidelines

	Tweet

PSA screening has declined in one large U.S. healthcare network since publication of two large screening trials and a set of guidelines, according to a study published online February 24 in the Journal of the National Cancer Institute.

In 2008, the U.S. Preventive Services Task Force issued guidelines recommending against PSA screening after age 75. The following year, investigators from two large screening trials reported contradictory results: The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial showed no difference in prostate cancer-specific mortality between screened versus non-screened men, while the European Randomized study of Screening for Prostate Cancer trial found a 20% reduction in mortality with screening.

Steven B. Zeliadt, Ph.D., of the VA Puget Sound Health Care System, Seattle, and colleagues report that after publication of the trials, PSA testing declined in the U.S. Veterans Health Administration Pacific Northwest Network. The decline was 3 percentage points among men aged 40-54; 2.7 percentage points among those aged 55-74; and 2.2 percentage points among men aged 75 years and older.

The authors conclude that the guidelines and the trial results may have had a modest effect on PSA screening among men in the Veteran’s Health Administration network.

In an editorial, Siu-Long Yao, M.D., and Grace Lu-Yao, Ph.D., of the Cancer Institute of New Jersey write that it is not surprising that the effect has been only modest, given the conflicting findings of the two large trials and other studies: “When faced with data that could be interpreted as neither strongly supportive nor decidedly unfavorable, it is natural that health-care providers and their patients might not substantially alter their practices in regard to PSA screening.”

###

Contacts:

Article: Jeri Rowe, Public Affairs Office, , (206) 764-2435

Editorial: Grace Lu-Yao; ; 732-235-8830

###

Contact: Caroline McNeil

301-841-1286
Journal of the National Cancer Institute

RELATED STORIES:
Gene variants in Japanese prostate cancer patients   Researchers find prostate cancer stem cell   Low PSA may not rule out prostate cancer   Researchers discover that same gene has opposite effects in prostate, breast cancers   Androgen deprivation therapy does not prevent prostate cancer from spreading   Guide aims to help men understand prostate cancer   Tissue spacers reduce risk of rectal injury for prostate cancer patients   Obesity-linked High Blood Volumes Render PSA Prostate Cancer Test Less Effective   University of Oklahoma Scientists Discover Way to Stop Pancreatic Cancer in Early Stages   Combination of genetic mutation and viral infection may cause prostate cancer   Folate may alter risk of prostate cancer progression   Statins don’t protect against cancer: study   Serum lipid levels and I-PSS or Qol are not linked in prostatic hyperplasia   Hopkins Prostate Cancer Experts Available   New diagnostic tool for prostate cancer   Xenotropic murine leukemia virus-related virus may not be associated with human prostate cancer   Researchers identify promising cancer drug target in prostate tumors   Prostate cancer screening improves quality of life by catching disease before it spreads   Standard Treatment for Prostate Cancer May Encourage Spread of Disease   Moderate exercise may lower prostate cancer risk   Study looks at using the immune system to reduce prostate cancer risk   Sexual side effects from prostrate drug

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]